Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 131

1.

Prediction value of XRCC 1 gene polymorphism on the survival of ovarian cancer treated by adjuvant chemotherapy.

Miao J, Zhang X, Tang QL, Wang XY, Kai L.

Asian Pac J Cancer Prev. 2012;13(10):5007-10.

PMID:
23244100
[PubMed - indexed for MEDLINE]
Free Article
2.

Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population.

Li K, Li W.

Mol Cell Biochem. 2013 Jan;372(1-2):27-33. doi: 10.1007/s11010-012-1442-4. Epub 2012 Sep 16.

PMID:
22983827
[PubMed - indexed for MEDLINE]
3.

Predictive value of XRCC1 and XRCC3 gene polymorphisms for risk of ovarian cancer death after chemotherapy.

Cheng CX, Xue M, Li K, Li WS.

Asian Pac J Cancer Prev. 2012;13(6):2541-5.

PMID:
22938418
[PubMed - indexed for MEDLINE]
Free Article
4.

Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer.

Przybylowska-Sygut K, Stanczyk M, Kusinska R, Kordek R, Majsterek I.

Clin Breast Cancer. 2013 Feb;13(1):61-8. doi: 10.1016/j.clbc.2012.09.019. Epub 2012 Oct 26.

PMID:
23103366
[PubMed - indexed for MEDLINE]
5.

Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.

Chang SJ, Bristow RE, Ryu HS.

Ann Surg Oncol. 2012 Dec;19(13):4059-67. doi: 10.1245/s10434-012-2446-8. Epub 2012 Jul 6.

PMID:
22766983
[PubMed - indexed for MEDLINE]
6.

BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.

Lesnock JL, Darcy KM, Tian C, Deloia JA, Thrall MM, Zahn C, Armstrong DK, Birrer MJ, Krivak TC.

Br J Cancer. 2013 Apr 2;108(6):1231-7. doi: 10.1038/bjc.2013.70. Epub 2013 Mar 5.

PMID:
23462720
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Kallikrein-related peptidase 10 (KLK10) expression and single nucleotide polymorphisms in ovarian cancer survival.

Batra J, Tan OL, O'Mara T, Zammit R, Nagle CM, Clements JA, Kedda MA, Spurdle AB.

Int J Gynecol Cancer. 2010 May;20(4):529-36. doi: 10.1111/IGC.0b013e3181d9273e.

PMID:
20686372
[PubMed - indexed for MEDLINE]
8.

Association between polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln genes and prognosis of colorectal cancer in a Chinese population.

Gan Y, Li XR, Chen DJ, Wu JH.

Asian Pac J Cancer Prev. 2012;13(11):5721-4.

PMID:
23317245
[PubMed - indexed for MEDLINE]
Free Article
9.

Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.

Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, Dimopoulos MA.

Oncology. 2013;84(3):158-65. doi: 10.1159/000341366. Epub 2012 Dec 28.

PMID:
23296063
[PubMed - indexed for MEDLINE]
10.

The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms.

Heubner M, Wimberger P, Riemann K, Kasimir-Bauer S, Otterbach F, Kimmig R, Siffert W.

Oncol Res. 2010;18(7):343-7.

PMID:
20377136
[PubMed - indexed for MEDLINE]
11.

XRCC1 and ADPRT polymorphisms associated with survival in breast cancer cases treated with chemotherapy.

Ye S, Rong J, Huang SH, Zheng ZS, Yun M, Wang SM.

Asian Pac J Cancer Prev. 2012;13(10):4923-6.

PMID:
23244082
[PubMed - indexed for MEDLINE]
Free Article
12.

Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.

Grivas A, Lianos E, Internos I, Papaxoinis G, Tselepatiotis E, Ziras N, Athanasiou AE.

J BUON. 2010 Oct-Dec;15(4):647-51.

PMID:
21229624
[PubMed - indexed for MEDLINE]
13.

The predictors of response to neoadjuvant chemotherapy in advanced epithelial ovarian cancer.

Yildirim Y, Ertas IE, Dogan A, Gultekin OE, Gultekin E.

J Surg Oncol. 2012 Feb;105(2):200-5. doi: 10.1002/jso.22053. Epub 2011 Aug 3.

PMID:
21815151
[PubMed - indexed for MEDLINE]
14.

Treatment of chemotherapy-induced anemia in ovarian cancer patients: does the use of erythropoiesis-stimulating agents worsen survival?

Rocconi RP, Sullivan P, Long B, Blaize M, Brown J, Arbuckle J, Bevis K, Estes JM, Reed E, Finan MA.

Int J Gynecol Cancer. 2012 Jun;22(5):786-91. doi: 10.1097/IGC.0b013e31825104f4.

PMID:
22552832
[PubMed - indexed for MEDLINE]
15.

From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer.

Aletti GD, Nordquist D, Hartmann L, Gallenberg M, Long HJ, Cliby WA.

Ann Oncol. 2010 Sep;21(9):1772-8. doi: 10.1093/annonc/mdq025. Epub 2010 Feb 5.

PMID:
20139154
[PubMed - indexed for MEDLINE]
Free Article
16.

Phase II clinical study on the GEMOX regimen as second- line therapy for advanced ovarian cancer.

Yuan SF, Zhang LP, Zhu LJ, Chen WJ, Zheng WE, Xiong JP.

Asian Pac J Cancer Prev. 2013;14(6):3949-53.

PMID:
23886213
[PubMed - indexed for MEDLINE]
Free Article
17.

Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery.

Saha A, Varughese M, Gallagher CJ, Orphanos G, Wilson P, Oram D, Jeyarajah A, Reynolds K, Shepherd J, McCormack M, Olaitan A, McDonald N, Mould T, McNeish I, Ledermann JA.

Int J Gynecol Cancer. 2012 May;22(4):566-72. doi: 10.1097/IGC.0b013e318247727f.

PMID:
22426404
[PubMed - indexed for MEDLINE]
18.

Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo.

Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, Tong D, Schuster E, Hefler L, Heim K, Mueller-Holzner E, Marth C, Moll UM, Zeimet AG, Zeillinger R.

Clin Cancer Res. 2005 Dec 1;11(23):8372-83.

PMID:
16322298
[PubMed - indexed for MEDLINE]
Free Article
19.

Kallikrein-related peptidase 3 (KLK3/PSA) single nucleotide polymorphisms and ovarian cancer survival.

O'Mara TA, Nagle CM, Batra J, Kedda MA, Clements JA, Spurdle AB.

Twin Res Hum Genet. 2011 Aug;14(4):323-7. doi: 10.1375/twin.14.4.323.

PMID:
21787114
[PubMed - indexed for MEDLINE]
20.

Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients.

Ke HG, Li J, Shen Y, You QS, Yan Y, Dong HX, Liu JH, Shen ZY.

Asian Pac J Cancer Prev. 2012;13(9):4413-6.

PMID:
23167352
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk